These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
998 related articles for article (PubMed ID: 27021436)
1. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Au Yeung CL; Co NN; Tsuruga T; Yeung TL; Kwan SY; Leung CS; Li Y; Lu ES; Kwan K; Wong KK; Schmandt R; Lu KH; Mok SC Nat Commun; 2016 Mar; 7():11150. PubMed ID: 27021436 [TBL] [Abstract][Full Text] [Related]
2. Adipocyte derived exosomes promote cell invasion and challenge paclitaxel efficacy in ovarian cancer. Williams ME; Howard D; Donnelly C; Izadi F; Parra JG; Pugh M; Edwards K; Lutchman-Sigh K; Jones S; Margarit L; Francis L; Conlan RS; Taraballi F; Gonzalez D Cell Commun Signal; 2024 Sep; 22(1):443. PubMed ID: 39285292 [TBL] [Abstract][Full Text] [Related]
4. Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer. Feng L; Shen F; Zhou J; Li Y; Jiang R; Chen Y Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32190895 [TBL] [Abstract][Full Text] [Related]
5. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells. Zheng P; Chen L; Yuan X; Luo Q; Liu Y; Xie G; Ma Y; Shen L J Exp Clin Cancer Res; 2017 Apr; 36(1):53. PubMed ID: 28407783 [TBL] [Abstract][Full Text] [Related]
6. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis. Eoh KJ; Lee SH; Kim HJ; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ Biochem Biophys Res Commun; 2018 Mar; 497(2):513-520. PubMed ID: 29452092 [TBL] [Abstract][Full Text] [Related]
7. Metformin Suppresses Tumor Progression by Inactivating Stromal Fibroblasts in Ovarian Cancer. Xu S; Yang Z; Jin P; Yang X; Li X; Wei X; Wang Y; Long S; Zhang T; Chen G; Sun C; Ma D; Gao Q Mol Cancer Ther; 2018 Jun; 17(6):1291-1302. PubMed ID: 29545331 [TBL] [Abstract][Full Text] [Related]
8. CAFs enhance paclitaxel resistance by inducing EMT through the IL‑6/JAK2/STAT3 pathway. Wang L; Zhang F; Cui JY; Chen L; Chen YT; Liu BW Oncol Rep; 2018 May; 39(5):2081-2090. PubMed ID: 29565447 [TBL] [Abstract][Full Text] [Related]
9. Combined expression of KLK4, KLK5, KLK6, and KLK7 by ovarian cancer cells leads to decreased adhesion and paclitaxel-induced chemoresistance. Loessner D; Quent VM; Kraemer J; Weber EC; Hutmacher DW; Magdolen V; Clements JA Gynecol Oncol; 2012 Dec; 127(3):569-78. PubMed ID: 22964375 [TBL] [Abstract][Full Text] [Related]
10. Shipping Drug Resistance: Extracellular Vesicles in Ovarian Cancer. Strandmann EPV; Müller R Trends Mol Med; 2016 Sep; 22(9):741-743. PubMed ID: 27474394 [TBL] [Abstract][Full Text] [Related]
11. Human adipose mesenchymal stem cell-derived exosomal-miRNAs are critical factors for inducing anti-proliferation signalling to A2780 and SKOV-3 ovarian cancer cells. Reza AMMT; Choi YJ; Yasuda H; Kim JH Sci Rep; 2016 Dec; 6():38498. PubMed ID: 27929108 [TBL] [Abstract][Full Text] [Related]
12. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells. Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254 [TBL] [Abstract][Full Text] [Related]
13. MiRNA-149 modulates chemosensitivity of ovarian cancer A2780 cells to paclitaxel by targeting MyD88. Zhan Y; Xiang F; Wu R; Xu J; Ni Z; Jiang J; Kang X J Ovarian Res; 2015 Jul; 8():48. PubMed ID: 26223974 [TBL] [Abstract][Full Text] [Related]
14. Acquisition of paclitaxel resistance via PI3K‑dependent epithelial‑mesenchymal transition in A2780 human ovarian cancer cells. Du F; Wu X; Liu Y; Wang T; Qi X; Mao Y; Jiang L; Zhu Y; Chen Y; Zhu R; Han X; Jin J; Ma X; Hua D Oncol Rep; 2013 Sep; 30(3):1113-8. PubMed ID: 23807572 [TBL] [Abstract][Full Text] [Related]
15. Highly expressed NRSN2 is related to malignant phenotype in ovarian cancer. Tang W; Ren A; Xiao H; Sun H; Li B Biomed Pharmacother; 2017 Jan; 85():248-255. PubMed ID: 27908706 [TBL] [Abstract][Full Text] [Related]
16. Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3/Rab proteins. Dorayappan KDP; Wanner R; Wallbillich JJ; Saini U; Zingarelli R; Suarez AA; Cohn DE; Selvendiran K Oncogene; 2018 Jul; 37(28):3806-3821. PubMed ID: 29636548 [TBL] [Abstract][Full Text] [Related]
17. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs. Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496 [TBL] [Abstract][Full Text] [Related]
18. Reversal of paclitaxel resistance in epithelial ovarian carcinoma cells by a MUC1 aptamer-let-7i chimera. Liu N; Zhou C; Zhao J; Chen Y Cancer Invest; 2012 Oct; 30(8):577-82. PubMed ID: 22812695 [TBL] [Abstract][Full Text] [Related]
19. Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells. Weiner-Gorzel K; Dempsey E; Milewska M; McGoldrick A; Toh V; Walsh A; Lindsay S; Gubbins L; Cannon A; Sharpe D; O'Sullivan J; Murphy M; Madden SF; Kell M; McCann A; Furlong F Cancer Med; 2015 May; 4(5):745-58. PubMed ID: 25684390 [TBL] [Abstract][Full Text] [Related]
20. Tumor-associated stromal cells as key contributors to the tumor microenvironment. Bussard KM; Mutkus L; Stumpf K; Gomez-Manzano C; Marini FC Breast Cancer Res; 2016 Aug; 18(1):84. PubMed ID: 27515302 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]